Modern concept of neovascular glaucoma (review)

Abstract

The aim of this study is analysis of current methods for diagnosis and treatment of neovascular glaucoma to assess their effectiveness, and based on these data, further development of a method of surgical treatment based on morphological factors involved in its progression. The review was performed using the domestic RSCI database and the international PubMed database, with the search keywords being “neovascular glaucoma”, “secondary glaucoma”, “ophthalmic hypertension”. An analysis of 39 literature sources was performed. The search depth was 13 years (2009–2022). Variants of neovascular glaucoma development of and of its diagnosis were considered, it was noted that it is necessary to pay attention to the study of minimally invasive methods for diagnosing the anterior segment using optical coherence tomography, which will help in the future to choose the right tactics for medical or surgical treatment. Particular attention is paid to the analysis of surgical treatment methods, which often turn out to be ineffective and require re-operations. It is necessary to develop a new method of surgical treatment of neovascular glaucoma, which provides the most sparing approach to surgical treatment, which will improve the anatomical and functional results and help reduce the number of intra- and postoperative complications and provide a longer period without re-operations.

Keywords

neovascular glaucoma / secondary glaucoma / ophtalmic hypertension

References

[1] Saikumar SJ, Manju A, Abhilash N. Neovascular glaucoma. J Ophthalmol. 2018;30(3):172–177. DOI: 10.4103/kjo.kjo_77_18

[2] Saikumar S.J., Manju A., Abhilash N. Neovascular glaucoma // J Ophthalmol. 2018. Vol. 30, No. 3. P. 172–177. DOI: 10.4103/kjo.kjo_77_18

[3] Senthil S, Dada T, Das T, et al. Neovascular glaucoma — A review. Indian J Ophtalmol. 2021;69(3):525–534. DOI: 10.4103/ijo.IJO_1591_20

[4] Senthil S., Dada T., Das T., et al. Neovascular glaucoma — A review // Indian J Ophtalmol. 2021. Vol. 69, No. 3. P. 525–534. DOI: 10.4103/ijo.IJO_1591_20

[5] de Salles MC, Lindberg C, Epstein D. Neovascular glaucoma in patients with central retinal vein occlusion: A real-life study in the anti-VEGF era. Acta Ophthalmologica. 2020;99(1):e7–e12. DOI: 10.1111/aos.14500

[6] de Salles M.C., Lindberg C., Epstein D. Neovascular glaucoma in patients with central retinal vein occlusion: A real-life study in the anti-VEGF era // Acta Ophthalmologica. 2020. Vol. 99, No. 1. P. e7–e12. DOI: 10.1111/aos.14500

[7] Havens SJ, Gulati V. Neovascular glaucoma. Ed. by Nguen QD, Rodrigues EB, Mieler WF. Retinal Pharmacotherapeutics. Vol. 55. Karger Publishers, 2016. P. 196–204. DOI: 10.1159/000431196

[8] Havens S.J., Gulati V. Neovascular glaucoma. Retinal Pharmacotherapeutics. Vol. 55 / Ed. by Q.D. Nguen, E.B. Rodrigues, W.F. Mieler. Karger Publishers, 2016. P. 196–204. DOI: 10.1159/000431196

[9] Jung YH, Ahn SJ, Hong JH, et al. Incidence and clinical features of neovascularization of the iris following acute central retinal artery occlusion. Korean J Ophthalmol. 2016;30(5):352–359. DOI: 10.3341/kjo.2016.30.5.352

[10] Jung Y.H., Ahn S.J., Hong J.H., et al. Incidence and clinical features of neovascularization of the iris following acute central retinal artery occlusion // Korean J Ophthalmol. 2016. Vol. 30, No. 5. P. 352–359. DOI: 10.3341/kjo.2016.30.5.352

[11] Rodrigues GB, Abe RY, Zangalli C, et al. Neovascular glaucoma: A review. Int J Retina Vitreous. 2016;2:26. DOI: 10.1186/s40942-016-0051-x

[12] Rodrigues G.B., Abe R.Y., Zangalli C., et al. Neovascular glaucoma: A review // Int J Retina Vitreous. 2016. Vol. 2. ID 26. DOI: 10.1186/s40942-016-0051-x

[13] Kim M, Lee C, Payne R, et al. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. Surv Ophthalmol. 2015;60(6):524–535. DOI: 10.1016/j.survophthal.2015.04.003.

[14] Kim M., Lee C., Payne R., et al. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review // Surv Ophthalmol. 2015. Vol. 60, No. 6. P. 524–535. DOI: 10.1016/j.survophthal.2015.04.003.

[15] Wand M. Cases in controversy: neovascular glaucoma. J Glaucoma. 1995;4(5):346–353. DOI: 10.1097/00061198-199510000-00009

[16] Wand M. Cases in controversy: neovascular glaucoma // J Glaucoma. 1995. Vol. 4, No. 5. P. 346–353. DOI: 10.1097/00061198-199510000-00009

[17] Hirano T, Kakihara S, Toriyama Y, et al. Wide-field en face swept-source optical coherence tomography angiography using extended field imaging in diabetic retinopathy. Br J Ophthalmol. 2018;102(9):1199–1203. DOI: 10.1136/bjophthalmol-2017-311358

[18] Hirano T., Kakihara S., Toriyama Y., et al. Wide-field en face swept-source optical coherence tomography angiography using extended field imaging in diabetic retinopathy // Br J Ophthalmol. 2018. Vol. 102, No. 9. P. 1199–1203. DOI: 10.1136/bjophthalmol-2017-311358

[19] Sawada O, Ichiyama Y, Obata S, et al. Comparison between wide-angle OCT angiography and ultra-wide field fluorescein angiography for detecting non-perfusion areas and retinal neovascularization in eyes with diabetic retinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2018;256(7):1275–1280. DOI: 10.1007/s00417-018-3992-y

[20] Sawada O., Ichiyama Y., Obata S., et al. Comparison between wide-angle OCT angiography and ultra-wide field fluorescein angiography for detecting non-perfusion areas and retinal neovascularization in eyes with diabetic retinopathy // Graefe’s Arch Clin Exp Ophthalmol. 2018. Vol. 256, No. 7. P. 1275–1280. DOI: 10.1007/s00417-018-3992-y

[21] Russell JF, Shi Y, Hinkle JW, et al. Longitudinal wide-field swept-source OCT angiography of neovascularization in proliferative diabetic retinopathy after panretinal photocoagulation. Ophthalmol Retina. 2019;3(4):350–361. DOI: 10.1016/j.oret.2018.11.008

[22] Russell J.F., Shi Y., Hinkle J.W., et al. Longitudinal wide-field swept-source OCT angiography of neovascularization in proliferative diabetic retinopathy after panretinal photocoagulation // Ophthalmol Retina. 2019. Vol. 3, No. 4. P. 350–361. DOI: 10.1016/j.oret.2018.11.008

[23] Chalam KV, Brar VS, Murthy RK. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol. 2014;132(11): 1350–1354. DOI: 10.1001/jamaophthalmol.2014.2356

[24] Chalam K.V., Brar V.S., Murthy R.K. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma // JAMA Ophthalmol. 2014. Vol. 132, No. 11. P. 1350–1354. DOI: 10.1001/jamaophthalmol.2014.2356

[25] Oshida E, Arai K, Sakai M, Chikuda M. Study of free radicals in aqueous humor in glaucoma and cataracts: differences in presence or absence of diabetes mellitus and neovascular glaucoma. Nippon Ganka Gakkai Zasshi. 2014;118(9):759–767.

[26] Oshida E., Arai K., Sakai M., Chikuda M. Study of free radicals in aqueous humor in glaucoma and cataracts: differences in presence or absence of diabetes mellitus and neovascular glaucoma // Nippon Ganka Gakkai Zasshi. 2014. Vol. 118, No. 9. P. 759–767.

[27] Strzalkowski P, Strzalkowska A, Göbel W, et al. Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma — a retrospective interventional case series. F1000Res. 2020;9:1236. DOI: 10.12688/f1000research.26879.2

[28] Strzalkowski P., Strzalkowska A., Göbel W., et al. Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma — a retrospective interventional case series // F1000Res. 2020. Vol. 9. ID 1236. DOI: 10.12688/f1000research.26879.2

[29] Andrés-Guerrero V, Perucho-González L, García-Feijoo J, et al. current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma. Adv Ther. 2017;34(2):378–395. DOI: 10.1007/s12325-016-0461-z

[30] Andrés-Guerrero V., Perucho-González L., García-Feijoo J., et al. current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma // Adv Ther. 2017. Vol. 34, No. 2. P. 378–395. DOI: 10.1007/s12325-016-0461-z

[31] Waisbourd M, Shemesh G, Kurtz S, et al. Topical bevacizumab for neovascular glaucoma: a pilot study. Pharmacology. 2014;93(3–4): 108–112. DOI: 10.1159/000358600

[32] 16.Waisbourd M., Shemesh G., Kurtz S., et al. Topical bevacizumab for neovascular glaucoma: a pilot study // Pharmacology. 2014. Vol. 93, No. 3–4. P. 108–112. DOI: 10.1159/000358600

[33] Grover S, Gupta S, Sharma R, et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009;93(2):273–274. DOI: 10.1136/bjo.2008.145714

[34] Grover S., Gupta S., Sharma R., et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma // Br J Ophthalmol. 2009. Vol. 93, No. 2. P. 273–274. DOI: 10.1136/bjo.2008.145714

[35] Lüke J, Nassar K, Lüke M, Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma — results from a prospective interventional case series. Graefe’s Arch Clin Exp Ophthalmol. 2013;251(10):2403–2413. DOI: 10.1007/s00417-013-2428-y

[36] Lüke J., Nassar K., Lüke M., Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma — results from a prospective interventional case series // Graefe’s Arch Clin Exp Ophthalmol. 2013. Vol. 251, No. 10. P. 2403–2413. DOI: 10.1007/s00417-013-2428-y

[37] Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefe’s Arch Clin Exp Ophthalmol. 2010;248(11):1601–1609. DOI: 10.1007/s00417-010-1406-x

[38] Sugimoto Y., Mochizuki H., Okumichi H., et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients // Graefe’s Arch Clin Exp Ophthalmol. 2010. Vol. 248, No. 11. P. 1601–1609. DOI: 10.1007/s00417-010-1406-x

[39] Karaman S, Leppänen V-M, Alitalo K. Vascular endothelial growth factor signaling in development and disease. Development. 2018;145(14): dev151019. DOI: 10.1242/dev.151019

[40] Karaman S., Leppänen V.-M., Alitalo K. Vascular endothelial growth factor signaling in development and disease // Development. 2018. Vol. 145, No. 14. ID dev151019. DOI: 10.1242/dev.151019

[41] Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28(2): 117–144. DOI: 10.1016/j.preteyeres.2008.11.005

[42] Rodrigues E.B., Farah M.E., Maia M., et al. Therapeutic monoclonal antibodies in ophthalmology // Prog Retin Eye Res. 2009. Vol. 28, No. 2. P. 117–144. DOI: 10.1016/j.preteyeres.2008.11.005

[43] Pardali E, ten Dijke P. Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci. 2009;14(13):4848–4861. DOI: 10.2741/3573

[44] Pardali E., ten Dijke P. Transforming growth factor-beta signaling and tumor angiogenesis // Front Biosci. 2009. Vol. 14, No. 13. P. 4848–4861. DOI: 10.2741/3573

[45] Nakamura Y, Takeda N, Mochizuki M. A case of vasoproliferative retinal tumor complicated by neovascular glaucoma. Retin Cases Brief Rep. 2013;7(4):338–342. DOI: 10.1097/ICB.0b013e3182598eea

[46] Nakamura Y., Takeda N., Mochizuki M. A case of vasoproliferative retinal tumor complicated by neovascular glaucoma // Retin Cases Brief Rep. 2013. Vol. 7, No. 4. P. 338–342. DOI: 10.1097/ICB.0b013e3182598eea

[47] Zhou Q, Liang J, Lu H. Intravitreal bevacizumab for ocular metastasis of multiple myeloma. Optom Vis Sci. 2013;90(9):e236–e240. DOI: 10.1097/OPX.0b013e31829caaf7

[48] Zhou Q., Liang J., Lu H. Intravitreal bevacizumab for ocular metastasis of multiple myeloma // Optom Vis Sci. 2013. Vol. 90, No. 9. P. e236–e240. DOI: 10.1097/OPX.0b013e31829caaf7

[49] Tang M, Fu Y, Wang Y, et al. Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma. BMC Ophthalmol. 2016;16:7. DOI: 10.1186/s12886-016-0183-7

[50] Tang M., Fu Y., Wang Y., et al. Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma // BMC Ophthalmol. 2016. Vol. 16. ID7. DOI: 10.1186/s12886-016-0183-7

[51] Sahyoun M, Azar G, Khoueir Z, et al. Long-term results of Ahmed glaucoma valve in association with intravitreal bevacizumab in neovascular glaucoma. J Glaucoma. 2015;24(5):383–388. DOI: 10.1097/IJG.0000000000000234

[52] Sahyoun M., Azar G., Khoueir Z., et al. Long-term results of Ahmed glaucoma valve in association with intravitreal bevacizumab in neovascular glaucoma // J Glaucoma. 2015. Vol. 24, No. 5. P. 383–388. DOI: 10.1097/IJG.0000000000000234

[53] Zhou M, Xu X, Zhang X, Sun X. Clinical outcomes of Ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: a systematic review and meta-analysis. J Glaucoma. 2015;25(7):551–557. DOI: 10.1097/IJG.0000000000000241

[54] Zhou M., Xu X., Zhang X., Sun X. Clinical outcomes of Ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: a systematic review and meta-analysis // J Glaucoma. 2015. Vol. 25, No. 7. P. 551–557. DOI: 10.1097/IJG.0000000000000241

[55] Borrás T. growth factors, oxidative damage, and inflammation in exfoliation syndrome. J Glaucoma. 2018;27S1(S1):S54–S60. DOI: 10.1097/IJG.0000000000000904

[56] Borrás T. growth factors, oxidative damage, and inflammation in exfoliation syndrome // J Glaucoma. 2018. Vol. 27S1, No. S1. P. S54–S60. DOI: 10.1097/IJG.0000000000000904

[57] Liu L, Xu Y, Huang Z, Wang X. Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications. BMC Ophthalmol. 2016;16:65. DOI: 10.1186/s12886-016-0248-7

[58] Liu L., Xu Y., Huang Z., Wang X. Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications // BMC Ophthalmol. 2016. Vol. 16. ID 65. DOI: 10.1186/s12886-016-0248-7

[59] Olmos LC, Sayed MS, Moraczewski AL, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye (Lond). 2016;30(3):463–472. DOI: 10.1038/eye.2015.259

[60] Olmos L.C., Sayed M.S., Moraczewski A.L., et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab // Eye (Lond). 2016. Vol. 30, No. 3. P. 463–472. DOI: 10.1038/eye.2015.259

[61] Molteno AC. New implant for drainage in glaucoma. Animal trial. Br J Ophthalmol. 1969;53(3):161–168. DOI: 10.1136/bjo.53.3.161

[62] Molteno A.C. New implant for drainage in glaucoma. Animal trial // Br J Ophthalmol. 1969. Vol. 53, No. 3. P. 161–168. DOI: 10.1136/bjo.53.3.161

[63] Hong M, Peng Y, Lai Y, et al. Comparison of Aurolab aqueous drainage implant with Ahmed glaucoma valve for refractory glaucoma: a meta-analysis. Ophthalmic Res. 2023;66(1):445–452. DOI: 10.1159/000529039

[64] Hong M., Peng Y., Lai Y., et al. Comparison of Aurolab aqueous drainage implant with Ahmed glaucoma valve for refractory glaucoma: a meta-analysis // Ophthalmic Res. 2023. Vol. 66, No. 1. P. 445–452. DOI: 10.1159/000529039

[65] Kang YK, Shin JP, Kim DW. Long-term surgical outcomes of Ahmed valve implantation in refractory glaucoma according to the type of glaucoma. BMC Ophthalmol. 2022;22(1):270. DOI: 10.1186/s12886-022-02493-w

[66] Kang Y.K., Shin J.P., Kim D.W. Long-term surgical outcomes of Ahmed valve implantation in refractory glaucoma according to the type of glaucoma // BMC Ophthalmol. 2022. Vol. 22, No. 1. ID 270. DOI: 10.1186/s12886-022-02493-w

[67] Williams AL, Moster MR, Rahmatnejad K, et al. Clinical efficacy and safety profile of micropulse transscleral cyclophotocoagulation in refractory glaucoma. J Glaucoma. 2018;27(5):445–449. DOI: 10.1097/IJG.0000000000000934

[68] Williams A.L., Moster M.R., Rahmatnejad K., et al. Clinical efficacy and safety profile of micropulse transscleral cyclophotocoagulation in refractory glaucoma // J Glaucoma. 2018. Vol. 27, No. 5. P. 445–449. DOI: 10.1097/IJG.0000000000000934

[69] Bar-David L, Blumenthal EZ. Evolution of glaucoma surgery in the last 25 years. Rambam Maimonides Med J. 2018;9(3):e0024. DOI: 10.5041/RMMJ.10345

[70] Bar-David L., Blumenthal E.Z. Evolution of glaucoma surgery in the last 25 years // Rambam Maimonides Med J. 2018. Vol. 9, No. 3. ID e0024. DOI: 10.5041/RMMJ.10345

[71] Tseng VL, Coleman AL, Chang MY, Caprioli J. Aqueous shunts for glaucoma. Cochrane Database Syst Rev. 2017;7(7):CD004918. DOI: 10.1136/bjo.2005.081224

[72] Tseng V.L., Coleman A.L., Chang M.Y., Caprioli J. Aqueous shunts for glaucoma // Cochrane Database Syst Rev. 2017. Vol. 7, No. 7. ID CD004918. DOI: 10.1136/bjo.2005.081224

[73] Hwang HB, Han JW, Yim HB, Lee NY. Beneficial effects of adjuvant intravitreal bevacizumab injection on outcomes of Ahmed glaucoma valve implantation in patients with neovascular glaucoma: systematic literature review. J Ocul Pharmacol Ther. 2015;31(4):198–203. DOI: 10.1089/jop.2014.0108

[74] Hwang H.B., Han J.W., Yim H.B., Lee N.Y. Beneficial effects of adjuvant intravitreal bevacizumab injection on outcomes of Ahmed glaucoma valve implantation in patients with neovascular glaucoma: systematic literature review // J Ocul Pharmacol Ther. 2015. Vol. 31, No. 4. P. 198–203. DOI: 10.1089/jop.2014.0108

[75] Kolko M, Heegaard S, Cvenkel B. Novel approaches to optimize treatment strategies in glaucoma. J Ophthalmol. 2021;2021:9876478. DOI: 10.1155/2021/9876478

[76] Kolko M., Heegaard S., Cvenkel B. Novel approaches to optimize treatment strategies in glaucoma // J Ophthalmol. 2021. Vol. 2021. ID 9876478. DOI: 10.1155/2021/9876478

[77] Thompson AM, Bevin TH, Molteno ACB. Surgical technique 1 (Molteno glaucoma implant). Ed. by Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG. Glaucoma. 2nd edition. Vol. 2. Elsevier, 2015. P. 1051–1063. DOI: 10.1016/B978-0-7020-5193-7.00111-4

[78] Thompson A.M., Bevin T.H., Molteno A.C.B. Surgical technique 1 (Molteno glaucoma implant). Glaucoma. 2nd edition. Vol. 2 / Ed. by T.M. Shaarawy, M.B. Sherwood, R.A. Hitchings, J.G. Crowston. Elsevier, 2015. P. 1051–1063. DOI: 10.1016/B978-0-7020-5193-7.00111-4

[79] Riva I, Roberti G, Oddone F, et al. Ahmed glaucoma valve implant: surgical technique and complications. Clin Ophthalmol. 2017;11: 357–367. DOI: 10.2147/OPTH.S104220

[80] Riva I., Roberti G., Oddone F., et al. Ahmed glaucoma valve implant: surgical technique and complications // Clin Ophthalmol. 2017. Vol. 11. P. 357–367. DOI: 10.2147/OPTH.S104220

[81] Kawabata K, Shobayashi K, Iwao K, et al. Efficacy and safety of Ex-PRESS® mini shunt surgery versus trabeculectomy for neovascular glaucoma: a retrospective comparative study. BMC Ophthalmol. 2019;19(1):75. DOI: 10.1186/s12886-019-1083-4

[82] Kawabata K., Shobayashi K., Iwao K., et al. Efficacy and safety of Ex-PRESS® mini shunt surgery versus trabeculectomy for neovascular glaucoma: a retrospective comparative study // BMC Ophthalmol. 2019. Vol. 19, No. 1. ID75. DOI: 10.1186/s12886-019-1083-4

RIGHTS & PERMISSIONS

Eco-Vector